{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:33:08Z","timestamp":1792175588869,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.euros.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T13:39:35Z","timestamp":1708090775000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association\u2013defined Intermediate-risk Non\u2013muscle-invasive Bladder Cancer Patients: A Phase 1b Study"],"prefix":"10.1016","volume":"62","author":[{"given":"F. Johannes","family":"P. van Valenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Cutie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Bhanvadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalaka","family":"Hampras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Sweiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Maffeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crysti","family":"Iarossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Stromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Michiel Sedelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.O.","family":"Steenbruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alfred Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2024.01.013_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2024.01.013_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2024.01.013_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2024.01.013_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2024.01.013_b0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2024.01.013_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0050","doi-asserted-by":"crossref","first-page":"9415","DOI":"10.18632\/oncotarget.24072","article-title":"Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer","volume":"9","author":"Kittler","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.euros.2024.01.013_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/02841868909111193","article-title":"Tumor cell proliferation kinetics and tumor growth rate","volume":"28","author":"Tubiana","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euros.2024.01.013_b0060","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4111\/icu.20210265","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane review","volume":"62","author":"Han","year":"2021","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1464-410X.2010.09496.x","article-title":"Pharmacokinetic study to optimize the intravesical administration of gemcitabine","volume":"106","author":"Gontero","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2024.01.013_b0070","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.urolonc.2022.02.009","article-title":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","volume":"40","author":"Daneshmand","year":"2022","journal-title":"Urol Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.euros.2024.01.013_b0075","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdj970","article-title":"Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors","volume":"17","author":"Cattel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2024.01.013_b0080","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0085","doi-asserted-by":"crossref","first-page":"LB-122","DOI":"10.1158\/1538-7445.AM2018-LB-122","article-title":"Abstract LB-122: Significant cytotoxic and immumomodulatory effects of continuous low dose intravesical gemcitabine in rodent bladder tumor models","volume":"78","author":"Giesing","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.euros.2024.01.013_b0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-160056","article-title":"The future of intravesical drug delivery for non-muscle invasive bladder cancer","volume":"2","author":"Douglass","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2024.01.013_b0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.euf.2019.09.006","article-title":"Overview of Taris GemRIS, a novel drug delivery system for bladder cancer","volume":"6","author":"Grimberg","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2024.01.013_b0100","first-page":"35","article-title":"The correlation between the plasma concentration of gemcitabine and short-term efficacy and adverse reactions in patients with advanced squamous cell carcinoma of the lung using liquid chromatography-mass spectrometry","author":"Xi","year":"2021","journal-title":"Ethiop J Health Dev"},{"key":"10.1016\/j.euros.2024.01.013_b0105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1179\/joc.2007.19.2.212","article-title":"Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule","volume":"19","author":"Peters","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.euros.2024.01.013_b0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4111\/icu.2019.60.1.35","article-title":"Evaluation of pain and catheter-related bladder discomfort relative to balloon volumes of indwelling urinary catheters: a prospective study","volume":"60","author":"Zugail","year":"2019","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/IJGM.S20267","article-title":"ABC of flexible cystoscopy for junior trainee and general practitioner","volume":"4","author":"Kadi","year":"2011","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.euros.2024.01.013_b0120","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.21037\/tcr-21-291","article-title":"Efficacy and toxicity in scheduled intravesical gemcitabine versus bacille Calmette-Gu\u00e9rin for Ta and T1 bladder cancer: a systematic review and meta-analysis","volume":"10","author":"Lu","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.euros.2024.01.013_b0125","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2024.01.013_b0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.2910510305","article-title":"Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times","volume":"51","author":"De Bruijn","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2024.01.013_b0135","first-page":"3849","article-title":"Pharmacodynamics of mitomycin C in cultured human bladder tumors","volume":"51","author":"Schmittgen","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.euros.2024.01.013_b0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2016.11.019","article-title":"Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2024.01.013_b0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.11.031","article-title":"Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery","volume":"245","author":"GuhaSarkar","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.euros.2024.01.013_b0150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euros.2024.01.013_b0155","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.03.025","article-title":"When and how to perform active surveillance for low-risk non-muscle-invasive bladder cancer","volume":"9","author":"Contieri","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2024.01.013_b0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euf.2021.01.019","article-title":"A systematic review of the efficacy and safety of outpatient bladder tumour ablation","volume":"8","author":"Malde","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2024.01.013_b0165","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000331727","article-title":"Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study","volume":"87","author":"Brausi","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.euros.2024.01.013_b0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"G\u00e5rdmark","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euros.2024.01.013_b0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1\u2013G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.01.013_b0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euros.2024.01.013_b0185","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.111","article-title":"LBA105: Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168324002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168324002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:11:36Z","timestamp":1762978296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168324002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":37,"alternative-id":["S2666168324002234"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2024.01.013","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association\u2013defined Intermediate-risk Non\u2013muscle-invasive Bladder Cancer Patients: A Phase 1b Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}